In Brief: Hoffmann-La Roche v. Organon Teknika
This article was originally published in The Gray Sheet
Hoffmann-La Roche v. Organon Teknika: Organon's NASBA HIV load tests do not infringe Hoffmann-La Roche patents, The District Court of The Hague, The Netherlands, confirms Sept. 12, upholding a Dec. 14, 1995 summary judgment decision by the court ("The Gray Sheet" Dec. 13, 1995, In Brief). Organon notes that "in other countries litigation between Teknika and Roche on the NASBA kit is still pending." The International Trade Commission decided July 22 to hear Roche's complaint that Organon's NASBA HIV-1 RNA QT kit infringes its U.S. patent 5,476,774 which allows precise quantification of nucleic acids ("The Gray Sheet" July 29, I&W-4)...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.